Suppression of Mutant Protein Expression in SCA3 and SCA1 Mice Using a CAG Repeat-Targeting Antisense Oligonucleotide

Molecular Therapy. Nucleic Acids
Eleni KourkoutaNicole A Datson

Abstract

Spinocerebellar ataxia type 3 (SCA3) and type 1 (SCA1) are dominantly inherited neurodegenerative disorders that are currently incurable. Both diseases are caused by a CAG-repeat expansion in exon 10 of the Ataxin-3 and exon 8 of the Ataxin-1 gene, respectively, encoding an elongated polyglutamine tract that confers toxic properties to the resulting proteins. We have previously shown lowering of the pathogenic polyglutamine protein in Huntington's disease mouse models using (CUG)7, a CAG repeat-targeting antisense oligonucleotide. Here we evaluated the therapeutic capacity of (CUG)7 for SCA3 and SCA1, in vitro in patient-derived cell lines and in vivo in representative mouse models. Repeated intracerebroventricular (CUG)7 administration resulted in a significant reduction of mutant Ataxin-3 and Ataxin-1 proteins throughout the brain of SCA3 and SCA1 mouse models, respectively. Furthermore, in both a SCA3 patient cell line and the MJD84.2 mouse model, (CUG)7 induced formation of a truncated Ataxin-3 protein species lacking the polyglutamine stretch, likely arising from (CUG)7-mediated exon 10 skipping. In contrast, skipping of exon 8 of Ataxin-1 did not significantly contribute to the Ataxin-1 protein reduction observed in (CUG)...Continue Reading

Citations

Nov 19, 2019·Brain : a Journal of Neurology·Ana C SilvaLuis Pereira de Almeida
Sep 24, 2020·Expert Opinion on Therapeutic Targets·Andreia Neves-CarvalhoPatrícia Maciel
Jul 11, 2020·Documenta Ophthalmologica. Advances in Ophthalmology·Ayane HiroseKazushige Tsunoda
Jul 14, 2020·Medicinal Research Reviews·Epaminondas Doxakis
Jul 23, 2020·Cellular and Molecular Life Sciences : CMLS·Adam CiesiolkaAgnieszka Fiszer
Jul 14, 2020·Current Opinion in Neurology·Maria do Carmo Costa
Apr 11, 2020·Journal of Translational Medicine·Magda M SantanaLuís Pereira de Almeida
Jul 6, 2020·Movement Disorders : Official Journal of the Movement Disorder Society·Maria do Carmo CostaGülin Öz
Dec 12, 2020·Nucleic Acid Therapeutics· Meena, Marc M Lemaitre
May 1, 2021·International Journal of Molecular Sciences·Ricardo Afonso-ReisClévio Nóbrega
May 26, 2021·Stem Cell Reviews and Reports·Marina P HommersomHans van Bokhoven
Aug 7, 2021·Toxins·Annika HeinzSybille Krauss
Oct 11, 2021·Movement Disorders : Official Journal of the Movement Disorder Society·Yaimeé Vázquez-MojenaLuis Velázquez-Pérez

❮ Previous
Next ❯

Datasets Mentioned

BETA
GM06153
GM06927

Methods Mentioned

BETA
antisense oligonucleotides
transfection
PCR
ELISA
Protein Assay

Clinical Trials Mentioned

NCT02519036

Software Mentioned

QuantaSoft
GraphPad Prism
Image Studio Lite

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Antisense Oligonucleotide Therapies: ND

Antisense oligonucleotides are synthetic DNA oligomers that hybridize to a target RNA. This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases.